The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy
Best Practice & Research Clinical Gastroenterology · 2024-09 · 72 · 101944
DOI: 10.1016/j.bpg.2024.101944 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Best Practice & Research Clinical Gastroenterology, 2024-09. Verfasst von Nathan J Dean und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Services Division, The Royal Marsden Hospital, London, United Kingdom. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Immune Checkpoint Inhibitors, Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Wellcome Trust, Institute for Cultural Inquiry, Imperial Experimental Cancer Medicine Centre.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) have revolutionised cancer therapy, yet the proportion of patients who achieve long-term disease control remain suboptimal. Over the past decade, the gut microbiome has been shown to influence immune-mediated tumour suppression as well as responses to ICI therapies. Compositional differences in gut microbiome may account for the differences in outcomes from immune checkpoint blockade. Identifying microbiota species associated with favourable/unfavourable outcomes and modelling their dynamics throughout the course of ICI treatment could help develop predictive biomarkers of immunotherapy response, and manipulating the gut microbiome represent a novel approach to enhancing ICI effectiveness. Clinically, this raises the prospect of using gut microbiome-based therapies to overcome primary resistance to ICIs, mitigate the effects of microbiome-altering drugs such as antibiotics or proton pump inhibitors, and improve overall survival in patients across numerous different cancer types.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Services Division, The Royal Marsden Hospital, London, United Kingdom.
- Cancer Services Division, The Royal Marsden Hospital, London, United Kingdom; Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom.
- Sussex Cancer Centre, University Hospitals Sussex NHS Foundation Trust, Brighton, United Kingdom.
- Department of Surgery and Cancer, Imperial College London, London, United Kingdom.
- Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom. Electronic address: nick.powell@nhs.net.
Förderung
- Wellcome Trust
- Institute for Cultural Inquiry
- Imperial Experimental Cancer Medicine Centre
- Cancer Treatment and Research Trust
- NIHR Imperial Biomedical Research Centre
Zitieren
APA
Dean, N. J., d'Arienzo, P. D., Ibraheim, H., Lee, K. A., Olsson-Brown, A. C., Pinato, D. J., & Powell, N. (2024). The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy. Best Practice & Research Clinical Gastroenterology, 72, 101944. https://doi.org/10.1016/j.bpg.2024.101944
Vancouver
Dean NJ, d'Arienzo PD, Ibraheim H, Lee KA, Olsson-Brown AC, Pinato DJ, et al. The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy. Best Practice & Research Clinical Gastroenterology. 2024;72:101944. doi:10.1016/j.bpg.2024.101944
BibTeX
@article{Dean2024,
author = {Dean, Nathan J and d'Arienzo, Paolo D and Ibraheim, Hajir and Lee, Karla A and Olsson-Brown, Anna C and Pinato, David J and Powell, Nicholas},
title = {The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy},
journal = {Best Practice & Research Clinical Gastroenterology},
year = {2024},
volume = {72},
pages = {101944},
doi = {10.1016/j.bpg.2024.101944}
}
EUVIMED